Thrombolytic therapy in acute myocardial infarction

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Thrombolytic therapy significantly reduces mortality and preserves left ventricular function in acute myocardial infarction.
• Despite proven benefits, thrombolytic therapy is underused in many countries.
• Current indications for thrombolysis can be expanded to include specific patient groups and prehospital settings.

Purpose of the Study:

• To review the current status and potential improvements in thrombolytic therapy for acute myocardial infarction.
• To highlight strategies for increasing the utilization and effectiveness of thrombolytic treatment.
• To emphasize the importance of rapid reperfusion for patient survival and quality of life.

Main Methods:

• Review of existing literature and clinical trial data on thrombolytic therapy for acute myocardial infarction.
• Analysis of factors contributing to underutilization and strategies for improvement.
• Discussion of adjunctive therapies and optimal reperfusion goals.

Main Results:

• Thrombolytic therapy is safe, cost-effective, and improves outcomes in acute myocardial infarction.
• Prehospital thrombolysis is feasible and cost-effective in certain settings.
• Achieving Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow is critical for ventricular function and survival.
• Optimal reperfusion is achieved in only about half of patients with current regimens.

Conclusions:

• Thrombolytic therapy is a cornerstone of acute myocardial infarction treatment but requires wider application.
• Shortening "door to needle" time and expanding indications are crucial for improving patient outcomes.
• Further advancements in thrombolytic, antiplatelet, and antithrombotic therapies are needed to enhance early and complete reperfusion, thereby improving survival and quality of life.